Brandon Norris, Abraham Chorbajian, John Dawi, Aishvaryaa Shree Mohan, Ira Glassman, Jacob Ochsner, Yura Misakyan, Arbi Abnousian, Anthony Kiriaki, Kayvan Sasaninia, Edith Avitia, Cesar Ochoa, Vishwanath Venketaraman
Thrombotic microangiopathy has been identified as a dominant mechanism for increased mortality and morbidity in coronavirus disease 2019 (COVID-19). In the context of severe COVID-19, patients may develop immunothrombosis within the microvasculature of the lungs, which contributes to the development of acute respiratory distress syndrome (ARDS), a leading cause of death in the disease. Immunothrombosis is thought to be mediated in part by increased levels of cytokines, fibrin clot formation, and oxidative stress...
February 22, 2024: Antioxidants (Basel, Switzerland)